![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Resistance Through Week 48 in the DAWNING Study Comparing Dolutegravir (DTG) Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir/Ritonavir (LPV/r) Plus 2 NRTIs in Second-line Treatment
|
|
|
Reported by Jules Levin
22nd International AIDS Conference, Amsterdam, Netherlands, July 23-27, 2018
Ruolan Wang,1Joe Horton,2Judy Hopking,3Karen King,2Kimberly Smith,1Michael Aboud,4Brian Wynne,5Jorg Sievers,4Mark Underwood1
1ViiV Healthcare, Research Triangle Park, NC, USA; 2Parexel International, Durham, NC, USA; 3GlaxoSmithKline, Stockley Park, UK; 4ViiV Healthcare, Brentford, UK; 5ViiV Healthcare, Philadelphia, PA, USA
![0731181](../images%20/073118/073118-5/0731181.gif)
![0731182](../images%20/073118/073118-5/0731182.gif)
![0731183](../images%20/073118/073118-5/0731183.gif)
![0731184](../images%20/073118/073118-5/0731184.gif)
![0731185](../images%20/073118/073118-5/0731185.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|